Search
Certara Inc
CERTAdd to Watchlist
6.970USD
+0.240+3.57%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.07BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.57%
5 Days
+28.36%
1 Month
+13.89%
6 Months
-20.25%
Year to Date
-20.89%
1 Year
-39.50%
Key Figures
6.740Open
7.050High
3.89MVolume
LossP/E TTM
16.04P/E Dynamic
--Dividend TTM
2.53%Turnover Ratio
6.730Prev. Close
6.740Low
19.32MTurnover
LossP/E Static
1.05P/B
0.00%Div Yield TTM
-0.99%ROA
13.88052wk High
1.03Volume Ratio
-12.05MNet Profit
153.33MShares
-0.0950EPS TTM
1.50Beta
-1.44%ROE
4.45052wk Low
4.61%Amplitude
47.43%Gross Margin
1.07BMarket Cap
5.78Reward/Risk
3.49%Risk Rate
TradingKey Stock Score of Certara Inc
Currency: USD Updated: 2026-07-01Key Insights
Certara Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 62 out of 486 in the Software & IT Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 7.71.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Certara Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Certara Inc Highlights
StrengthsRisks
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.20% year-on-year.
Undervalued
The company’s latest PE is -70.88, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 177.30M shares, decreasing 20.60% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 241.12K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.27.
Analyst Rating
Based on
13
analysts
Hold
Current Rating
7.709
Target Price
+21.21%
Upside Space
Certara Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Certara Inc Info
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
Ticker SymbolCERT
CompanyCertara Inc
CEOFeehery (William F)
Websitehttps://www.certara.com/
Related Instruments
-1.78%
-0.36%
-0.48%
+1.62%
-4.90%
+2.99%
+3.24%
-1.64%
+4.66%
+2.84%
+1.03%
-1.13%
-1.87%
+2.17%
-6.65%
+2.42%
+1.76%
-0.16%
-1.72%
+0.34%Popular Instruments
FAQs
What is the current price of Certara Inc (CERT)?
The current price of Certara Inc (CERT) is 6.73.
What is the symbol of Certara Inc?
The ticker symbol of Certara Inc is CERT.
What is the 52-week high of Certara Inc?
The 52-week high of Certara Inc is 13.88.
What is the 52-week low of Certara Inc?
The 52-week low of Certara Inc is 4.45.
What is the market capitalization of Certara Inc?
The market capitalization of Certara Inc is 1.05B.
Is Certara Inc (CERT) currently rated as Buy, Hold, or Sell?
According to analysts, Certara Inc (CERT) has an overall rating of signal_hold, with a price target of 7.71.
What is the Earnings Per Share (EPS TTM) of Certara Inc (CERT)?
The Earnings Per Share (EPS TTM) of Certara Inc (CERT) is -0.01.